Main Menu

Professional Activities

Professor David Dearnaley, Clinical Academic Radiotherapy (Dearnaley) team

Awards, Prizes or Honours

Humphrey Rolleston Travel Exhibition, University of Cambridge, 1971.

Calergo Award, European Society for Radiotherapy and Oncology, 1992.

Award for Excellence in Radiation Oncology 2011, EMUC (European Multidisciplinary Meeting on Urological Cancers), 2011.

First Prize for Best Oral Presentation, ESMO, ESTRO, EAU, 2015.

Senior Investigator Emeritus, NIHR, 2015.

Editorial Boards

Prostate Cancer and Prostatic Diseases, 1997-2002.

Urological Cancer Abstracts, 1999-2010.

Cancer Topics, 1997-2005.

External Committees

Prostate Cancer Risk Management Programme: Scientific Reference Group, Member, NHS, 2001-2007.

NCRI Radiotherapy Study Group, Member, National Cancer Research Institute, 2000-2008.

RCR Working Party on the Implementation of Conformal Radiotherapy in the UK, Member, Royal College of Radiologists, 2001-2001.

NCRN Brachytherapy Group, Chair, National Cancer Research Network, 2004-2005.

External Advisory Committee, Member, Irish Clinical Oncology Research Group, 2004-2008.

Scientific Committee for London Meeting, Chair, Prostate Cancer Research Foundation, 2005-2006.

TNM Expert Advisory Panel on Genito-Urinary Cancer, Member, Union for Cancer Control, 2005-2013.

HTA Clinical Trials Board, Member, NHS Research and Development, 2006-2010.

Urology Tumour Working Group, Chair 2006-2010, NHS SW London Cancer Network, 1998-2013.

NCRI Prostate Cancer Study Group, Chair 1998-2003, National Cancer Research Institute, 1998-2008.

BOA Council, Member, British Oncological Association, 1998-2001.

NIHR Specialist Biomedical Research Centre, Urology/Prostate Cancer Lead, NIHR, 2007-2018.

NIHR, Senior Investigator, National Institute of Health Research, 2008-2015.

Scientific Committee, ESTRO representative, EMUC, 2011-2016.

College of Experts, Member, NHS Research and Development HTA Clinical Trials Board, 2012.

Advisory Committee on Clinical Excellence Awards (ACCEA), Member, NHS, 2014-2017.

GU Symposium Program Committee, Committee Member, American Society of Clinical Oncology (ASCO), 2014-2017.

Executive Committee, Scientific and Medical Advisor, Bob Champion Cancer Trust, 2016.

Hypofractionated for Prostate Radiotherapy Working Group, Clinical Lead, NHS England & NHS Improvement, 2016-2018.

Docetaxol in Hormone Sensitive Localised Prostate Cancer, Clinical Lead, NHS England & NHS Improvement, 2017.

Clinical Evidence Review Panel: Prostate Radiotherapy in Low Volume Metastatic Disease, Clinical Lead, NHS England & NHS Improvement, 2018.

Trial Steering Committee, Scientific Adviser, Department of Health funded PROTECT Trial, 2001.

CHHiP Trial Management Group, Chair, Cancer Research UK, 2002.

Trial Steering and Trial Management Group PROMPTS Trial, Chair, Cancer Research UK, 2010.

Trial Steering Group and Management Groups STAMPEDE Trial, Member, Cancer Research UK, 2003.

Independent Data Monitoring Committee NIMRAD Trial, Member, Cancer Research UK, 2010.

Trial Steering and Management Committees POPS Trial, Chair, National Institute for Health Research (NIHR), 2015.

Radiation Assurance, Radiation Assurance Reviewer, HRA Health Assurance Authority, Radiation Assurance, 2018.

Centre of Excellence Management Group, Member, Prostate Cancer UK, 2014.